Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study
Abstract Microencapsulation represents a process that can create targeted, controlled release kinetics of drugs, thus optimizing therapeutic efficacy. Our group has investigated the impact of this technology on Wistar rats to determine pharmacological efficacy of basil extracts. Animals were treated...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b8b5c19a74854da7831800f59217337c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b8b5c19a74854da7831800f59217337c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b8b5c19a74854da7831800f59217337c2021-11-14T12:21:30ZPharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study10.1038/s41598-021-01713-52045-2322https://doaj.org/article/b8b5c19a74854da7831800f59217337c2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01713-5https://doaj.org/toc/2045-2322Abstract Microencapsulation represents a process that can create targeted, controlled release kinetics of drugs, thus optimizing therapeutic efficacy. Our group has investigated the impact of this technology on Wistar rats to determine pharmacological efficacy of basil extracts. Animals were treated with water extract of Ocimum basilicum in microvesicles and with combination of basil extracts and 3α,7α-dihydroxy-12-keto-5-cholanate, also known as 12-monoketocholic acid (MKC) acid in microvesicles for 7 days. Alloxan was used to induce hyperglycemia. Pharmacological effects on glycemia were evaluated by measuring blood glucose levels in alloxan-induced diabetic rats. Microvesicles were prepared using the Büchi-based microencapsulating system developed in our lab. The dose of basil extract that was orally administered in rats was 200 mg/kg and the dose of MKC acid was 4 mg/kg as per established protocols. A seven-day treatment with basil aqueous extract, as well as a combination of basil and MKC acid extract in the pharmaceutical formulation, led to a statistically significant reduction in the blood glucose concentration of animals with alloxan-induced hyperglycemia compared to pre-treatment values (p < 0.05 and p < 0.01), which indicates that basil has hypoglycemic and antihyperglycemic effects. Microvesicles, as a pharmaceutical-technological formulation, substantially enhance the hypolipidemic action of basil extract with MKC acid.Branislava TeofilovicSvetlana Golocorbin-KonNebojsa StilinovicNevena Grujic-LeticAleksandar RaškovicArmin MooranianHani Al-SalamiMomir MikovNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Branislava Teofilovic Svetlana Golocorbin-Kon Nebojsa Stilinovic Nevena Grujic-Letic Aleksandar Raškovic Armin Mooranian Hani Al-Salami Momir Mikov Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study |
| description |
Abstract Microencapsulation represents a process that can create targeted, controlled release kinetics of drugs, thus optimizing therapeutic efficacy. Our group has investigated the impact of this technology on Wistar rats to determine pharmacological efficacy of basil extracts. Animals were treated with water extract of Ocimum basilicum in microvesicles and with combination of basil extracts and 3α,7α-dihydroxy-12-keto-5-cholanate, also known as 12-monoketocholic acid (MKC) acid in microvesicles for 7 days. Alloxan was used to induce hyperglycemia. Pharmacological effects on glycemia were evaluated by measuring blood glucose levels in alloxan-induced diabetic rats. Microvesicles were prepared using the Büchi-based microencapsulating system developed in our lab. The dose of basil extract that was orally administered in rats was 200 mg/kg and the dose of MKC acid was 4 mg/kg as per established protocols. A seven-day treatment with basil aqueous extract, as well as a combination of basil and MKC acid extract in the pharmaceutical formulation, led to a statistically significant reduction in the blood glucose concentration of animals with alloxan-induced hyperglycemia compared to pre-treatment values (p < 0.05 and p < 0.01), which indicates that basil has hypoglycemic and antihyperglycemic effects. Microvesicles, as a pharmaceutical-technological formulation, substantially enhance the hypolipidemic action of basil extract with MKC acid. |
| format |
article |
| author |
Branislava Teofilovic Svetlana Golocorbin-Kon Nebojsa Stilinovic Nevena Grujic-Letic Aleksandar Raškovic Armin Mooranian Hani Al-Salami Momir Mikov |
| author_facet |
Branislava Teofilovic Svetlana Golocorbin-Kon Nebojsa Stilinovic Nevena Grujic-Letic Aleksandar Raškovic Armin Mooranian Hani Al-Salami Momir Mikov |
| author_sort |
Branislava Teofilovic |
| title |
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study |
| title_short |
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study |
| title_full |
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study |
| title_fullStr |
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study |
| title_full_unstemmed |
Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study |
| title_sort |
pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/b8b5c19a74854da7831800f59217337c |
| work_keys_str_mv |
AT branislavateofilovic pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy AT svetlanagolocorbinkon pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy AT nebojsastilinovic pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy AT nevenagrujicletic pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy AT aleksandarraskovic pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy AT arminmooranian pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy AT hanialsalami pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy AT momirmikov pharmacologicaleffectsofnovelmicrovesiclesofbasilonbloodglucoseandthelipidprofileapreclinicalstudy |
| _version_ |
1718429252074864640 |